🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Lycia Therapeutics, Inc. (LYCA)
NASDAQ: LYCA · Real-Time Price · USD
33.07
+1.30 (4.09%)
At close: Nov 20, 2026, 4:00 PM EST
33.30
+0.23 (0.70%)
After-hours: Nov 20, 2026, 7:30 PM EST

Company Description

Lycia Therapeutics, Inc., a biotechnology company, engages in the discovery and development of therapeutics designed to degrade disease-causing extracellular proteins for the treatment of autoimmune, inflammatory, and allergic diseases.

The company develops the LYTAC platform, a modular technology designed to create therapeutics that selectively reduce the levels of pathogenic proteins.

Its therapeutic candidate LCA-0061 degrades immunoglobulin E (IgE) for the treatment of allergic diseases, including food allergy.

The company also develops LCA-0062, a follow-on program designed to degrade IgE for the treatment of allergic diseases.

Additionally, it develops LCA-0321, a candidate designed to selectively degrade TSHR autoantibodies (thyrotropin receptor antibodies, or TRAbs), the pathogenic drivers of Graves' disease.

Lycia Therapeutics, Inc. was incorporated in 2019 and is headquartered in South San Francisco, California.

Lycia Therapeutics, Inc.
Lycia Therapeutics logo
CountryUnited States
Founded2019
IPO DateOct 23, 2026
IndustryBiotechnology
SectorHealthcare
Employees31
CEOAetna Trombley

Contact Details

Address:
400 East Jamie Court, Suite 200
South San Francisco, California 94080
United States
Phone(650) 392-3357
Websitelyciatx.com

Stock Details

Ticker SymbolLYCA
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
IPO Price$18.00
CIK Code1806540
CUSIP Number55081P100
ISIN NumberUS55081P1003
Employer ID84-3860514
SIC Code2836

Key Executives

NamePosition
Aetna Wun Trombley, Ph.D.President, Chief Executive Officer and Director
Amy BachrodtChief Financial Officer
Chin Lee, M.D.Chief Medical Officer
Steve Staben, Ph.D.Chief Scientific Officer
Sofia Touami, Ph.D.Chief Business Officer
William J. RieflinChair and Director
Tim AndersonDirector
Ming FangDirector
Laurent Fischer, M.D.Director
Jane Pritchett HendersonDirector

Latest SEC Filings

DateTypeTitle
Oct 30, 2026SCHEDULE 13GFiling
Oct 26, 20268-KCurrent Report
Oct 23, 2026S-8Securities to be offered to employees in employee benefit plans
Oct 23, 2026424B4Prospectus
Oct 22, 2026EFFECTNotice of Effectiveness
Oct 22, 2026S-1MEFRegistration adding securities to prior Form S-1 registration
Oct 22, 2026CERTCertification by an exchange approving securities for listing
Oct 20, 20268-A12BRegistration of securities
Oct 20, 2026S-1/A[Amend] General form for registration of securities under the Securities Act of 1933
Oct 5, 2026S-1General form for registration of securities under the Securities Act of 1933
Investor Relations Documents
Annual and quarterly reports, earnings releases, and presentation slides